These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17688389)

  • 41. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
    Shakir SA; Layton D
    Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 43. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post-market surveillance of consumer products: Framework for adverse event management.
    Kingston R; Sioris K; Gualtieri J; Brutlag A; Droege W; Osimitz TG
    Regul Toxicol Pharmacol; 2021 Nov; 126():105028. PubMed ID: 34481892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance.
    Arlett P
    Drug Saf; 2019 May; 42(5):581-582. PubMed ID: 30637598
    [No Abstract]   [Full Text] [Related]  

  • 47. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. France's competent authority initiatives.
    Jullian E
    Stud Health Technol Inform; 1996; 28():93-5. PubMed ID: 10164094
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
    Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
    Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 52. [Practical value of active prospective monitoring of drug therapy safety].
    Ovchinnikova EA; Nazimkin KE; Iagudina RI
    Antibiot Khimioter; 2006; 51(9-10):40-6. PubMed ID: 18030790
    [No Abstract]   [Full Text] [Related]  

  • 53. Signal selection and follow-up in pharmacovigilance.
    Meyboom RH; Lindquist M; Egberts AC; Edwards IR
    Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of statistical methods for safety signal detection: a simulation study.
    Chen M; Zhu L; Chiruvolu P; Jiang Q
    Pharm Stat; 2015; 14(1):11-9. PubMed ID: 25329607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Postmarketing surveillance for dog and cat vaccines: new resources in changing times.
    Moore GE; Frana TS; Guptill LF; Ward MP; Lewis HB; Glickman LT
    J Am Vet Med Assoc; 2005 Oct; 227(7):1066-9. PubMed ID: 16220664
    [No Abstract]   [Full Text] [Related]  

  • 56. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postmarketing safety reports for human drug and biological products; electronic submission requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(111):33072-92. PubMed ID: 24922981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulatory innovation in postmarketing risk assessment and management.
    Staffa JA; Dal Pan GJ
    Clin Pharmacol Ther; 2012 Mar; 91(3):555-7. PubMed ID: 22297386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exemption of radiopharmaceuticals from <797>.
    Hung JC; VanBrocklin HF
    J Nucl Med; 2004 Oct; 45(10):14N. PubMed ID: 15551510
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.